Brian Booth

• RNAfix uses ADAR-recruiting guide RNAs to achieve >90% in vivo A-to-I editing efficiency in mouse and NHP CNS with exquisite transcriptome-wide specificity

• Shape’s novel AAV capsid SHP-DB1 efficiently crosses the NHP blood-brain-barrier following IV administration, delivering RNA editing across the entire brain without invasive cranial injections

• ShapeTX’s integrated platform combines AI-optimized RNAfix guide RNAs, proprietary CNS-tropic AAV capsids, and disruptive stable cell line AAV manufacturing to overcome key gene therapy limitations, enabling scalable, cost-effective solutions to address unmet needs in neurological disorders